125 related articles for article (PubMed ID: 8845858)
21. Association between genetic variation in the myo-inositol monophosphatase 2 (IMPA2) gene and age at onset of bipolar disorder.
Tomioka Y; Jiménez E; Salagre E; Arias B; Mitjans M; Ruiz V; Sáiz P; García-Portilla MP; de la Fuente L; Gomes-da-Costa SP; Bobes J; Vieta E; Benabarre A; Grande I
J Affect Disord; 2018 May; 232():229-236. PubMed ID: 29499505
[TBL] [Abstract][Full Text] [Related]
22. Myo-inositol monophosphatase: diverse effects of lithium, carbamazepine, and valproate.
Vadnal R; Parthasarathy R
Neuropsychopharmacology; 1995 Jul; 12(4):277-85. PubMed ID: 7576004
[TBL] [Abstract][Full Text] [Related]
23. Defective craniofacial development and brain function in a mouse model for depletion of intracellular inositol synthesis.
Ohnishi T; Murata T; Watanabe A; Hida A; Ohba H; Iwayama Y; Mishima K; Gondo Y; Yoshikawa T
J Biol Chem; 2014 Apr; 289(15):10785-10796. PubMed ID: 24554717
[TBL] [Abstract][Full Text] [Related]
24. Behavioral analyses of transgenic mice harboring bipolar disorder candidate genes, IMPA1 and IMPA2.
Ohnishi T; Watanabe A; Ohba H; Iwayama Y; Maekawa M; Yoshikawa T
Neurosci Res; 2010 May; 67(1):86-94. PubMed ID: 20153384
[TBL] [Abstract][Full Text] [Related]
25. Myo-inositol-1-phosphate (MIP) synthase: a possible new target for antibipolar drugs.
Agam G; Shamir A; Shaltiel G; Greenberg ML
Bipolar Disord; 2002; 4 Suppl 1():15-20. PubMed ID: 12479670
[TBL] [Abstract][Full Text] [Related]
26. Does inositol signalling have a role in disease susceptibility and drug treatment of bipolar disorder?
Steen VM
Bipolar Disord; 2002; 4 Suppl 1():53-5. PubMed ID: 12479678
[No Abstract] [Full Text] [Related]
27. A safe lithium mimetic for bipolar disorder.
Singh N; Halliday AC; Thomas JM; Kuznetsova OV; Baldwin R; Woon EC; Aley PK; Antoniadou I; Sharp T; Vasudevan SR; Churchill GC
Nat Commun; 2013; 4():1332. PubMed ID: 23299882
[TBL] [Abstract][Full Text] [Related]
28. Human chromosomal localization of a gene for inositol monophosphatase by fluorescence in situ hybridization.
Vadnal R; Heng HH; Parthasarathy L; Parthasarathy R
Neuroreport; 1998 Mar; 9(4):683-5. PubMed ID: 9559938
[TBL] [Abstract][Full Text] [Related]
29. Characterization of two genes, Impa1 and Impa2 encoding mouse myo-inositol monophosphatases.
Shamir A; Sjøholt G; Ebstein RP; Agam G; Steen VM
Gene; 2001 Jun; 271(2):285-91. PubMed ID: 11418250
[TBL] [Abstract][Full Text] [Related]
30. High-resolution structure of myo-inositol monophosphatase, the putative target of lithium therapy.
Gill R; Mohammed F; Badyal R; Coates L; Erskine P; Thompson D; Cooper J; Gore M; Wood S
Acta Crystallogr D Biol Crystallogr; 2005 May; 61(Pt 5):545-55. PubMed ID: 15858264
[TBL] [Abstract][Full Text] [Related]
31. Beryllium competitively inhibits brain myo-inositol monophosphatase, but unlike lithium does not enhance agonist-induced inositol phosphate accumulation.
Faraci WS; Zorn SH; Bakker AV; Jackson E; Pratt K
Biochem J; 1993 Apr; 291 ( Pt 2)(Pt 2):369-74. PubMed ID: 8387266
[TBL] [Abstract][Full Text] [Related]
32. cDNA cloning of human and rat brain myo-inositol monophosphatase. Expression and characterization of the human recombinant enzyme.
McAllister G; Whiting P; Hammond EA; Knowles MR; Atack JR; Bailey FJ; Maigetter R; Ragan CI
Biochem J; 1992 Jun; 284 ( Pt 3)(Pt 3):749-54. PubMed ID: 1377913
[TBL] [Abstract][Full Text] [Related]
33. Effects of lithium on phosphoinositide metabolism in vivo.
Sherman WR; Gish BG; Honchar MP; Munsell LY
Fed Proc; 1986 Oct; 45(11):2639-46. PubMed ID: 3019784
[TBL] [Abstract][Full Text] [Related]
34. Crystal structure of human myo-inositol monophosphatase 2, the product of the putative susceptibility gene for bipolar disorder, schizophrenia, and febrile seizures.
Arai R; Ito K; Ohnishi T; Ohba H; Akasaka R; Bessho Y; Hanawa-Suetsugu K; Yoshikawa T; Shirouzu M; Yokoyama S
Proteins; 2007 May; 67(3):732-42. PubMed ID: 17340635
[TBL] [Abstract][Full Text] [Related]
35. Inositol monophosphatase--a putative target for Li+ in the treatment of bipolar disorder.
Atack JR; Broughton HB; Pollack SJ
Trends Neurosci; 1995 Aug; 18(8):343-9. PubMed ID: 7482796
[TBL] [Abstract][Full Text] [Related]
36. Inositol-deficient food augments a behavioral effect of long-term lithium treatment mediated by inositol monophosphatase inhibition: an animal model with relevance for bipolar disorder.
Shtein L; Agam G; Belmaker RH; Bersudsky Y
J Clin Psychopharmacol; 2015 Apr; 35(2):175-7. PubMed ID: 25679134
[TBL] [Abstract][Full Text] [Related]
37. Altered IMPA2 gene expression and calcium homeostasis in bipolar disorder.
Yoon IS; Li PP; Siu KP; Kennedy JL; Cooke RG; Parikh SV; Warsh JJ
Mol Psychiatry; 2001 Nov; 6(6):678-83. PubMed ID: 11673796
[TBL] [Abstract][Full Text] [Related]
38. Genetic history as a predictor of lithium response in manic-depressive illness.
Mendlewicz J; Fieve RR; Stallone F; Fleiss JL
Lancet; 1972 Mar; 1(7750):599-600. PubMed ID: 4110088
[No Abstract] [Full Text] [Related]
39. Lithium modulation of the human inositol monophosphatase 2 (IMPA2) promoter.
Seelan RS; Parthasarathy LK; Parthasarathy RN
Biochem Biophys Res Commun; 2004 Nov; 324(4):1370-8. PubMed ID: 15504365
[TBL] [Abstract][Full Text] [Related]
40. Inositol monophosphatase activity from the Escherichia coli suhB gene product.
Matsuhisa A; Suzuki N; Noda T; Shiba K
J Bacteriol; 1995 Jan; 177(1):200-5. PubMed ID: 8002619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
